IMNM Quote, Financials, Valuation and Earnings

Context Therapeutics, Inc. has a net margin of -1080.87% compared to Immunome, Inc.'s net margin of --. Immunome, Inc.'s return on equity of -90.08% beat Context Therapeutics, Inc.'s return on equity of -31.05%.

Immunome, Inc. has a consensus price target of $34.25, signalling upside risk potential of 57.76%. On the other hand Context Therapeutics, Inc. has an analysts' consensus of $5.57 which suggests that it could grow by 393.05%. Given that Context Therapeutics, Inc. has higher upside potential than Immunome, Inc., analysts believe Context Therapeutics, Inc. is more attractive than Immunome, Inc..

Immunome, Inc. has a beta of 2.175, which suggesting that the stock is 117.492% more volatile than S&P 500. In comparison Context Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Immunome, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Context Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunome, Inc. pays -- of its earnings as a dividend. Context Therapeutics, Inc. pays out -- of its earnings as a dividend.

Immunome, Inc. quarterly revenues are --, which are smaller than Context Therapeutics, Inc. quarterly revenues of --. Immunome, Inc.'s net income of -$57.5M is lower than Context Therapeutics, Inc.'s net income of -$9.7M. Notably, Immunome, Inc.'s price-to-earnings ratio is -- while Context Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunome, Inc. is 177.80x versus -- for Context Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -1080.87% compared to Immunome, Inc.'s net margin of 31.72%. Immunome, Inc.'s return on equity of -90.08% beat Eli Lilly & Co.'s return on equity of 106.26%.

Immunome, Inc. has a consensus price target of $34.25, signalling upside risk potential of 57.76%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.44%. Given that Immunome, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Immunome, Inc. is more attractive than Eli Lilly & Co..

Immunome, Inc. has a beta of 2.175, which suggesting that the stock is 117.492% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Immunome, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Immunome, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Immunome, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Immunome, Inc.'s net income of -$57.5M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Immunome, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunome, Inc. is 177.80x versus 16.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Prelude Therapeutics, Inc. has a net margin of -1080.87% compared to Immunome, Inc.'s net margin of -303.46%. Immunome, Inc.'s return on equity of -90.08% beat Prelude Therapeutics, Inc.'s return on equity of -106.36%.

Immunome, Inc. has a consensus price target of $34.25, signalling upside risk potential of 57.76%. On the other hand Prelude Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 63.27%. Given that Prelude Therapeutics, Inc. has higher upside potential than Immunome, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than Immunome, Inc..

Immunome, Inc. has a beta of 2.175, which suggesting that the stock is 117.492% more volatile than S&P 500. In comparison Prelude Therapeutics, Inc. has a beta of 1.065, suggesting its more volatile than the S&P 500 by 6.517%.

Immunome, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prelude Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunome, Inc. pays -- of its earnings as a dividend. Prelude Therapeutics, Inc. pays out -- of its earnings as a dividend.

Immunome, Inc. quarterly revenues are --, which are smaller than Prelude Therapeutics, Inc. quarterly revenues of $6.5M. Immunome, Inc.'s net income of -$57.5M is lower than Prelude Therapeutics, Inc.'s net income of -$19.7M. Notably, Immunome, Inc.'s price-to-earnings ratio is -- while Prelude Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunome, Inc. is 177.80x versus 16.52x for Prelude Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Relay Therapeutics, Inc. has a net margin of -1080.87% compared to Immunome, Inc.'s net margin of -10395.13%. Immunome, Inc.'s return on equity of -90.08% beat Relay Therapeutics, Inc.'s return on equity of -41.21%.

Immunome, Inc. has a consensus price target of $34.25, signalling upside risk potential of 57.76%. On the other hand Relay Therapeutics, Inc. has an analysts' consensus of $14.60 which suggests that it could grow by 70.56%. Given that Relay Therapeutics, Inc. has higher upside potential than Immunome, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Immunome, Inc..

Immunome, Inc. has a beta of 2.175, which suggesting that the stock is 117.492% more volatile than S&P 500. In comparison Relay Therapeutics, Inc. has a beta of 1.501, suggesting its more volatile than the S&P 500 by 50.076%.

Immunome, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relay Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunome, Inc. pays -- of its earnings as a dividend. Relay Therapeutics, Inc. pays out -- of its earnings as a dividend.

Immunome, Inc. quarterly revenues are --, which are smaller than Relay Therapeutics, Inc. quarterly revenues of --. Immunome, Inc.'s net income of -$57.5M is higher than Relay Therapeutics, Inc.'s net income of -$74.1M. Notably, Immunome, Inc.'s price-to-earnings ratio is -- while Relay Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunome, Inc. is 177.80x versus 174.21x for Relay Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.